Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide

Leukemia and Lymphoma

Volumn 44, Issue 6, 2003, Pages 993-996

  Dimopoulos, Meletios A ^a   Hamilos, George ^a   Efstathiou, Eleni ^a   Siapkaras, Ioannis ^a   Matsouka, Charis ^a   Gika, Dimitra ^a   Grigoraki, Vassiliki ^b   Papadimitriou, Christos ^a   Mitsibounas, Dimitrios ^a   Anagnostopoulos, Nikolaos ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

Chemotherapy; Fludarabine and cyclophosphamide; Therapy; Waldenstrom's macroglobulinemia

Indexed keywords

BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; HEMOGLOBIN; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; ONDANSETRON; PREDNISONE; RITUXIMAB; STEROID; THALIDOMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD VISCOSITY; CANCER GRADING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LYMPHOMA; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RELAPSE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0037409660     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000077025     Document Type: Article

References (16)

1. Harris, N.L., Jaffe, E.S. and Diebold (1999) "World Health Organization classificatin of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997", J. Clin. Oncol. 17, 3835-3849.
2. Kyle, R.A. and Garton, J.P. (1987) "The spectrum of IgM monoclonal gammopathy in 430 cases", Mayo Clin. Proc. 62, 719-731.
3. Dimopoulos, M.A., Panayiotidis, P. and Moulopoulos, L.A. (2000) "Waldenstrom's macroglobulinemia: clinical features, complications and management", J. Clin. Oncol. 18, 214-226.
4. Kyle, R.A., Greipp, P.R. and Gertz, M.A. (2000) "Waldenstrom's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil", Br. J. Haematol. 108, 737-742.
5. Dimopoulos, M.A., Kantarjian, H. and Weber, D. (1994) "Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxy-adenosine", J. Clin. Oncol. 12, 2694-2698.
6. Dimopoulos, M.A., O'Brien, S. and Kantargian, H. (1993) "Fludarabine therapy in Waldenstrom's macroglobulinemia", Am. J. Med. 95, 49-52.
7. Foran, J.M., Rohatiner, A.Z.S. and Coiffier, B. (1999) "Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldnstrom's macroglobulinemia, and mantle-cell lymphoma", J. Clin. Oncol. 17, 546-553.
8. Dhodapkar, M.V., Jacobson, J.L. and Gertz, M.A. (2001) "Prognostic factors and response to fludarabine therapy in patients with Waldenstrom's macroglobulinemia: results of United States intergroup trial", Blood 98, 41-48.
9. Leblond, V., Ben-Othman, T. and Deconinck, E. (1998) "Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases", J. Clin. Oncol. 16, 2060-2064.
10. Leblond, V., Levy, V. and Maloisel, F. (2001) "Multicenter randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom's macroglobulinemia in first relapse or with primary refractory disease", Blood 98, 2640-2644.
11. Lossos, I.S., Paltiel, O. and Polliack, A. (1999) "Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphoma", Leuk. Lymphoma 33, 155-160.
12. Hochster, H.S., Oken, M.M., Winter, J.N., Gordon, L.I., Raphael, B.G., Bennet, J.M. and Cassileth, P.A. (2000) "Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results an long-term follow-up a report from the Eastern Cooperative Oncology Group", J. Clin. Oncol. 18, 987-994.
13. Flinn, I.W., Byrd, J.C., Morrison, C., Jamison, J., Diehl, L.F., Murphy, T., Piantadosi, S., Seifter, E., Ambinder, R.F., Vogelsang, G. and Grever, M.R. (2000) "Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies", Blood 96, 71-75.
14. O'Brien, S.M., Kantarjian, H.M., Cortes, J., Berom, M., Koller, C.A., Giles, F.J., Lerner, S. and Keating, M. (2001) "Results of fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia", J. Clin. Oncol. 19, 1414-1420.
15. Lazzarino, M., Orlandi, E., Montillo, M., Tedeschi, A., Pagnuco, G., Astori, C., Corso, A., Brusamolino, E., Simoucini, L., Morra, E. and Bernasconi (1999) "Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is offective in pretreated low-grade non-Hodgkin's lymphoma", Ann. Oncol. 10, 59-64.
16. Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J. and Anagnostopoulos, N. (2002) "Treatment of Waldenstrom's macroglobulinemia with rituximab", J. Clin. Oncol. 20, 2327-2333.